Loading…
Lobbying Spend
—
Filings
18
Firms Hired
2
Active Period
2018–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
2018 · fourth_quarter · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client expense: — · Firm income: —
Matched citations: HR 5202
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
2018 · fourth_quarter · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client expense: — · Firm income: —
Matched citations: S 916
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
2018 · third_quarter · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client expense: — · Firm income: $30,000
Matched citations: HR 5202
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
2018 · third_quarter · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client expense: — · Firm income: $30,000
Matched citations: S 916
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
2018 · third_quarter · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client expense: — · Firm income: —
Matched citations: HR 5202
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
2018 · third_quarter · Firm: WAXMAN STRATEGIES
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client expense: — · Firm income: —
Matched citations: S 916
Source: Senate LDA